CDT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Conduit Pharmaceuticals's annualized Net Income for the quarter that ended in Mar. 2024 was $-14.21 Mil. Conduit Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2024 was $6.07 Mil. Therefore, Conduit Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -234.05%.
The historical rank and industry rank for Conduit Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
During the past 3 years, Conduit Pharmaceuticals's highest Return-on-Tangible-Asset was 3.53%. The lowest was -7.41%. And the median was -7.41%.
The historical data trend for Conduit Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Conduit Pharmaceuticals Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
Return-on-Tangible-Asset | - | - | -7.41 |
Conduit Pharmaceuticals Quarterly Data | ||||||||
Dec21 | Mar22 | Sep22 | Dec22 | Mar23 | Sep23 | Dec23 | Mar24 | |
Return-on-Tangible-Asset | Get a 7-Day Free Trial | - | -83,600.00 | 132.17 | 73.98 | -234.05 |
For the Biotechnology subindustry, Conduit Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Conduit Pharmaceuticals's Return-on-Tangible-Asset falls into.
Conduit Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -0.535 | / | ( (0 | + | 7.224) | / 1 ) | |
= | -0.535 | / | 7.224 | ||||
= | -7.41 % |
Conduit Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | -14.208 | / | ( (7.224 | + | 4.917) | / 2 ) | |
= | -14.208 | / | 6.0705 | ||||
= | -234.05 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.
Conduit Pharmaceuticals (NAS:CDT) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Intelmed Llc | other: See Responses | 11421 GOLDEN EAGLE COURT, NAPLES FL 34120 |
Jennifer Isacoff Mcnealey | director | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
David Tapolczay | director, officer: Chief Executive Officer | 32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU |
Andrew Regan | director, 10 percent owner | LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133 |
Faith L. Charles | director | ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019 |
Algo Holdings, Inc. | 10 percent owner, other: See Responses | 100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309 |
Corvus Capital Ltd. | 10 percent owner, other: See Responses | WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107 |
Freda C Lewis-hall | director | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
James Bligh | director | 38 OXBERRY AVENUE, LONDON X0 SW6 5SS |
Shaolin Capital Management Llc | 10 percent owner | 230 NW 24TH STREET, SUITE 603, MIAMI FL 33127 |
Richard Edward Feinberg | director | 2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103 |
Murphy Canyon Acquisition Sponsor, Llc | 10 percent owner | 4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123 |
Chele Chiavacci Farley | director | 4 RIDGE ROAD, TUXEDO PARK NY 10987 |
Bentzen Edwin H Iv | officer: Chief Accounting Officer | 2513 BIRCH HOLLOW ST, HENDERSON NV 89044 |
Jack Kendrick Heilbron | director, officer: CEO, President, and Chairman | 16433 BRONCO LANE, POWAY CA 92064 |
From GuruFocus
By Marketwired • 09-22-2023
By Marketwired • 10-11-2023
By Marketwired • 11-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.